Real-time, label-free assessment of HER2-targeted antibody-drug-conjugate therapies

Antibody-drug conjugates (ADCs), particularly those targeted toward the tumor antigen HER2, have emerged as a popular and effective treatment for cancer patients.

Discover how the effectiveness of ADC therapies in early development were assessed using the Maestro Z™, and how this instrument uses electrodes embedded at the bottom of the well to measure this process in real time so researchers can reveal the precise kinetics of ADC cytotoxicity.